HC Wainwright reissued their buy rating on shares of BiomX (NYSEMKT:PHGE – Free Report) in a research report released on Friday morning, Benzinga reports. The brokerage currently has a $2.00 price objective on the stock.
Separately, Laidlaw assumed coverage on shares of BiomX in a research note on Tuesday, May 28th. They set a buy rating and a $2.50 price target on the stock.
Check Out Our Latest Analysis on BiomX
BiomX Stock Performance
BiomX shares are scheduled to reverse split before the market opens on Monday, August 26th. The 1-10 reverse split was announced on Thursday, August 15th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, August 23rd.
Hedge Funds Weigh In On BiomX
An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC bought a new stake in BiomX Inc. (NYSEMKT:PHGE – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by institutional investors.
BiomX Company Profile
BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
Recommended Stories
- Five stocks we like better than BiomX
- The How And Why of Investing in Oil Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- 3 Warren Buffett Stocks to Buy Now
- 2 Option Strategies to Maximize Profits in a Bear Market
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.